Market closed
Merck KGaA/€MRK
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About Merck KGaA
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Ticker
€MRK
Sector
Trading on
XETRA
Industry
Pharmaceuticals
Headquarters
Employees
59,020
Website
Merck KGaA Metrics
BasicAdvanced
€56B
20.28
€6.39
0.74
€2.20
1.70%
Price and volume
Market cap
€56B
Beta
0.74
52-week high
€176.25
52-week low
€125.70
Average daily volume
342K
Dividend rate
€2.20
Financial strength
Current ratio
1.191
Quick ratio
0.686
Long term debt to equity
23.333
Total debt to equity
34.351
Dividend payout ratio (TTM)
37.13%
Interest coverage (TTM)
17.13%
Management effectiveness
Return on assets (TTM)
4.80%
Return on equity (TTM)
9.82%
Valuation
Price to earnings (TTM)
20.283
Price to revenue (TTM)
2.662
Price to book
1.87
Price to tangible book (TTM)
12.51
Price to free cash flow (TTM)
23.275
Dividend yield (TTM)
1.70%
Forward dividend yield
1.70%
Growth
Revenue change (TTM)
0.78%
Earnings per share change (TTM)
-1.60%
3-year revenue growth (CAGR)
2.43%
3-year earnings per share growth (CAGR)
-3.14%
3-year dividend per share growth (CAGR)
5.95%
What the Analysts think about Merck KGaA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Merck KGaA stock.
Merck KGaA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Merck KGaA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Merck KGaA News
AllArticlesVideos
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck & Co., Inc. Lawsuit - MRK
Accesswire·18 hours ago
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Accesswire·18 hours ago
Levi & Korsinsky Reminds Merck & Co., Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK
Accesswire·23 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe
Capital at risk
Market closed
Upcoming events
Apr28
Merck KGaA
Dividend·Ex-dividend
Apr30
Merck KGaA
Dividend·Payment
€2.20
Per share
FAQs
What’s the current market cap for Merck KGaA stock?
Merck KGaA (MRK) has a market cap of €56B as of March 29, 2025.
What is the P/E ratio for Merck KGaA stock?
The price to earnings (P/E) ratio for Merck KGaA (MRK) stock is 20.28 as of March 29, 2025.
Does Merck KGaA stock pay dividends?
Yes, the Merck KGaA (MRK) stock pays dividends to shareholders. As of March 29, 2025, the dividend rate is €2.2 and the yield is 1.7%. Merck KGaA has a payout ratio of 37.13% on a trailing twelve-month basis.
When is the next Merck KGaA dividend payment date?
The next Merck KGaA (MRK) dividend payment is scheduled for April 30, 2025.
What is the beta indicator for Merck KGaA?
Merck KGaA (MRK) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.